182 related articles for article (PubMed ID: 18537180)
1. The antiviral drug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound.
Warner N; Locarnini S
Hepatology; 2008 Jul; 48(1):88-98. PubMed ID: 18537180
[TBL] [Abstract][Full Text] [Related]
2. The impact of the hepatitis B virus polymerase rtA181T mutation on replication and drug resistance is potentially affected by overlapping changes in surface gene.
Ahn SH; Park YK; Park ES; Kim JH; Kim DH; Lim KH; Jang MS; Choe WH; Ko SY; Sung IK; Kwon SY; Kim KH
J Virol; 2014 Jun; 88(12):6805-18. PubMed ID: 24696492
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis B e antigen-suppressing mutations enhance the replication efficiency of adefovir-resistant hepatitis B virus strains.
Herbers U; Amini-Bavil-Olyaee S; Mueller A; Luedde T; Trautwein C; Tacke F
J Viral Hepat; 2013 Feb; 20(2):141-8. PubMed ID: 23301549
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis B virus rtA181T/sW172non-stop mutation may increase resistance fold to adefovir- and entecavir-resistant mutants compared to rtA181T/sW172* mutation.
Zhao L; Li X; Cheng Y; Chen R; Shao J; Zhou Y; Li Q; Liao H; Zhao Y; Liu L; Su H; Liu Y; Liu Y; Xu D
Antiviral Res; 2018 Jun; 154():26-34. PubMed ID: 29630974
[TBL] [Abstract][Full Text] [Related]
5. Possible Involvement of Multidrug-Resistant Hepatitis B Virus sW172* Truncation Variant in the ER Stress Signaling Pathway during Hepatocarcinogenesis.
Zheng J; Jiang S; Lu F
Jpn J Infect Dis; 2016 Jul; 69(4):306-13. PubMed ID: 26567840
[TBL] [Abstract][Full Text] [Related]
6. The oncogenic potential of hepatitis B virus rtA181T/ surface truncation mutant.
Lai MW; Yeh CT
Antivir Ther; 2008; 13(7):875-9. PubMed ID: 19043921
[TBL] [Abstract][Full Text] [Related]
7. Complementation of Wild-Type and Drug-Resistant Hepatitis B Virus Genomes to Maintain Viral Replication and Rescue Virion Production under Nucleos(t)ide Analogs.
Wu C; Li B; Zhang X; Zhao K; Chen Y; Yuan Y; Liu Y; Chen R; Xu D; Chen X; Lu M
Virol Sin; 2019 Aug; 34(4):377-385. PubMed ID: 31218588
[TBL] [Abstract][Full Text] [Related]
8. Development of HBV S gene mutants in chronic hepatitis B patients receiving nucleotide/nucleoside analogue therapy.
Yeh CT
Antivir Ther; 2010; 15(3 Pt B):471-5. PubMed ID: 20516567
[TBL] [Abstract][Full Text] [Related]
9. [Clinical characteristics and effect of secondary individualized therapy in chronic hepatitis B patients infected with the rtA181 mutation hepatitis B virus].
Ji FZ; Wang L; Yang BH; Zhao JJ; Liu F; Xue Y; Li T
Zhonghua Gan Zang Bing Za Zhi; 2012 Apr; 20(4):280-4. PubMed ID: 22964149
[TBL] [Abstract][Full Text] [Related]
10. [Clinical emergence features and implications of hepatitis B virus rtA181T mutation].
Li X; Jiang L; Li F; Liu Y; Dai J; Zhao P; Qin Y; Li J; Xu D
Zhonghua Gan Zang Bing Za Zhi; 2015 Jan; 23(1):23-7. PubMed ID: 25751382
[TBL] [Abstract][Full Text] [Related]
11. Supportive role played by precore and preS2 genomic changes in the establishment of lamivudine-resistant hepatitis B virus.
Ohkawa K; Takehara T; Kato M; Deguchi M; Kagita M; Hikita H; Sasakawa A; Kohga K; Uemura A; Sakamori R; Yamaguchi S; Miyagi T; Ishida H; Tatsumi T; Hayashi N
J Infect Dis; 2008 Oct; 198(8):1150-8. PubMed ID: 18713056
[TBL] [Abstract][Full Text] [Related]
12. Biological characteristics comparison of HBV rtA181T mutants with truncated or substituted HBsAg expression in vitro and in vivo model systems.
Zhou LY; Chen EQ; Wang ML; Chen LL; Liu CP; Zeng F; Tang H
Sci Rep; 2016 Dec; 6():39260. PubMed ID: 27976732
[TBL] [Abstract][Full Text] [Related]
13. In vitro characterization of viral fitness of therapy-resistant hepatitis B variants.
Villet S; Billioud G; Pichoud C; Lucifora J; Hantz O; Sureau C; Dény P; Zoulim F
Gastroenterology; 2009 Jan; 136(1):168-176.e2. PubMed ID: 18996386
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis B virus mutations associated with antiviral therapy.
Bartholomeusz A; Locarnini S
J Med Virol; 2006; 78 Suppl 1():S52-5. PubMed ID: 16622878
[TBL] [Abstract][Full Text] [Related]
15. Impact of hepatitis B e antigen-suppressing mutations on the replication efficiency of entecavir-resistant hepatitis B virus strains.
Amini-Bavil-Olyaee S; Herbers U; Luedde T; Trautwein C; Tacke F
J Viral Hepat; 2011 Nov; 18(11):804-14. PubMed ID: 20887378
[TBL] [Abstract][Full Text] [Related]
16. Nucleos(t)ide analogues causes HBV S gene mutations and carcinogenesis.
Wang ML; Tang H
Hepatobiliary Pancreat Dis Int; 2016 Dec; 15(6):579-586. PubMed ID: 27919846
[TBL] [Abstract][Full Text] [Related]
17. Basal core promoter and precore mutations in the hepatitis B virus genome enhance replication efficacy of Lamivudine-resistant mutants.
Tacke F; Gehrke C; Luedde T; Heim A; Manns MP; Trautwein C
J Virol; 2004 Aug; 78(16):8524-35. PubMed ID: 15280461
[TBL] [Abstract][Full Text] [Related]
18. Biological characteristics of the rtA181T/sW172* mutant strain of Hepatitis B virus in animal model.
Dai J; Chen EQ; Bai L; Gong DY; Zhou QL; Cheng X; Huang FJ; Tang H
Virol J; 2012 Nov; 9():280. PubMed ID: 23171829
[TBL] [Abstract][Full Text] [Related]
19. In vitro resistance to interferon-alpha of hepatitis B virus with basic core promoter double mutation.
Wang Y; Wei L; Jiang D; Cong X; Fei R; Chen H; Xiao J; Wang Y
Antiviral Res; 2007 Aug; 75(2):139-45. PubMed ID: 17397939
[TBL] [Abstract][Full Text] [Related]
20. A dominant hepatitis B virus population defective in virus secretion because of several S-gene mutations from a patient with fulminant hepatitis.
Kalinina T; Riu A; Fischer L; Will H; Sterneck M
Hepatology; 2001 Aug; 34(2):385-94. PubMed ID: 11481624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
